Presentation is loading. Please wait.

Presentation is loading. Please wait.

Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Low-Dose Total Body Irradiation after Rejection of First Allografts  Boglarka.

Published byΒάλιος Τρικούπη Modified over 5 years ago

Similar presentations

Presentation on theme: "Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Low-Dose Total Body Irradiation after Rejection of First Allografts  Boglarka."— Presentation transcript:

1 Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Low-Dose Total Body Irradiation after Rejection of First Allografts  Boglarka Gyurkocza, Thai M. Cao, Rainer F. Storb, Thoralf Lange, Wendy Leisenring, Georg N. Franke, Mohamed Sorror, Richard Hoppe, David G. Maloney, Robert S. Negrin, Judith A. Shizuru, Brenda M. Sandmaier  Biology of Blood and Marrow Transplantation  Volume 15, Issue 10, Pages (October 2009) DOI: /j.bbmt Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

2 Figure 1 Outcomes of salvage HCT. Neutrophil engraftment (A). Thirty-three of 38 patients had sustained engraftment (probability of engraftment: 0.87; 95% CI: 0.74, 0.95). The median time to neutrophil engraftment was 15 (range: 9-42) days. Survival (B). The 2- and 4-year estimated probabilities of survival were 0.49 (95% CI: 0.31, 0.66) and 0.42 (95% CI: 0.23, 0.61), respectively. NRM (C). The 2-year estimated probability of NRM was 0.24 (95% CI: 0.11, 0.41). Relapse/progression (D). The estimated probability of relapse/progression at 2 years was 0.36 (95% CI: 0.20, 0.52). The dashed lines represent 95% CI. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

3 Figure 2 GVHD. Grades II-IV aGVHD (A). The cumulative incidence of grades II-IV aGVHD at day 100 was 0.42 (95% CI: 0.26, 0.57). The cumulative incidences of grade III and grade IV aGVHD were 0.05, each (95% CI: 0.009, 016). Moderate-severe cGVHD (B). The cumulative incidence of moderate-severe cGVHD at 2 years was 0.41 (95% CI: 0.25, 0.57). The dashed lines represent 95% CI. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

4 Figure 3 Impact of donor type (A), using same versus different donor (B), TBI dose (C), and HCT-CI score (D) for OS. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

Download ppt "Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Low-Dose Total Body Irradiation after Rejection of First Allografts  Boglarka."

Similar presentations

Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors.

Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors.
Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,

Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,
Radiolabeled Anti-CD45 Antibody with Reduced-Intensity Conditioning and Allogeneic Transplantation for Younger Patients with Advanced Acute Myeloid Leukemia.

Radiolabeled Anti-CD45 Antibody with Reduced-Intensity Conditioning and Allogeneic Transplantation for Younger Patients with Advanced Acute Myeloid Leukemia.
Relative Survival of Long-Term Hematopoietic Cell Transplant Recipients Approaches General Population Rates  Ian Nivison-Smith, Judy M. Simpson, Anthony.

Relative Survival of Long-Term Hematopoietic Cell Transplant Recipients Approaches General Population Rates  Ian Nivison-Smith, Judy M. Simpson, Anthony.
Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.
Incidence and Causes of Hospital Readmission in Pediatric Patients after Hematopoietic Cell Transplantation  David Stephen Shulman, Wendy B. London, Dongjing.

Incidence and Causes of Hospital Readmission in Pediatric Patients after Hematopoietic Cell Transplantation  David Stephen Shulman, Wendy B. London, Dongjing.
Impact of Postgrafting Immunosuppressive Regimens on Nonrelapse Mortality and Survival after Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant.

Impact of Postgrafting Immunosuppressive Regimens on Nonrelapse Mortality and Survival after Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant.
Predictive Value of Circulating Angiopoietin-2 for Endothelial Damage–Related Complications in Allogeneic Hematopoietic Stem Cell Transplantation  Norihiro.

Predictive Value of Circulating Angiopoietin-2 for Endothelial Damage–Related Complications in Allogeneic Hematopoietic Stem Cell Transplantation  Norihiro.
Single and Multiple Dose MultiStem (Multipotent Adult Progenitor Cell) Therapy Prophylaxis of Acute Graft-versus-Host Disease in Myeloablative Allogeneic.

Single and Multiple Dose MultiStem (Multipotent Adult Progenitor Cell) Therapy Prophylaxis of Acute Graft-versus-Host Disease in Myeloablative Allogeneic.
Efficacy of a Viral Load-Based, Risk-Adapted, Preemptive Treatment Strategy for Prevention of Cytomegalovirus Disease after Hematopoietic Cell Transplantation 

Efficacy of a Viral Load-Based, Risk-Adapted, Preemptive Treatment Strategy for Prevention of Cytomegalovirus Disease after Hematopoietic Cell Transplantation 
Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia  Scott R. Solomon, Connie A. Sizemore, Xu Zhang,

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia  Scott R. Solomon, Connie A. Sizemore, Xu Zhang,
Allogeneic Transplantation with Reduced-Intensity Conditioning for Hodgkin and non- Hodgkin Lymphoma: Importance of Histology for Outcome  Philippe Armand,

Allogeneic Transplantation with Reduced-Intensity Conditioning for Hodgkin and non- Hodgkin Lymphoma: Importance of Histology for Outcome  Philippe Armand,
Extended Mycophenolate Mofetil and Shortened Cyclosporine Failed to Reduce Graft- versus-Host Disease after Unrelated Hematopoietic Cell Transplantation.

Extended Mycophenolate Mofetil and Shortened Cyclosporine Failed to Reduce Graft- versus-Host Disease after Unrelated Hematopoietic Cell Transplantation.
Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide 

HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide 
Absolute Lymphocyte Count on Day 30 Is a Surrogate for Robust Hematopoietic Recovery and Strongly Predicts Outcome after T Cell-Depleted Allogeneic Stem.

Absolute Lymphocyte Count on Day 30 Is a Surrogate for Robust Hematopoietic Recovery and Strongly Predicts Outcome after T Cell-Depleted Allogeneic Stem.
Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility?  Jason W. Chien, Keith M. Sullivan  Biology.

Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility?  Jason W. Chien, Keith M. Sullivan  Biology.
Betty T. Tran, Abigail Halperin, Jason W. Chien 

Betty T. Tran, Abigail Halperin, Jason W. Chien 
Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center  Takahiro Fukuda, Michael.

Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center  Takahiro Fukuda, Michael.
Re: Twenty-Year Follow-Up in Patients with Aplastic Anemia Given Marrow Grafts from HLA-Identical Siblings and Randomized to Receive Methotrexate/Cyclosporine.

Re: Twenty-Year Follow-Up in Patients with Aplastic Anemia Given Marrow Grafts from HLA-Identical Siblings and Randomized to Receive Methotrexate/Cyclosporine.

Similar presentations

Ads by Google